Get regular updates to your inbox.
In advance of Sarcoidosis Awareness Month in April, the Foundation for Sarcoidosis Research (FSR) and aTyr Pharma will hold a virtual town hall about sarcoidosis and considerations for transitioning from standard corticosteroids to new therapies. The meeting, which is open to anyone, will be held online at…
The Foundation for Sarcoidosis Research (FSR) has trained its first group of volunteer patients tasked with educating and championing better treatments and outcomes for people living with sarcoidosis in the U.S. The 60 newly trained volunteer leaders will team up with and support members of the foundation’s…
People with pulmonary sarcoidosis believe earlier referrals to specialists could improve the diagnostic process and call for new treatment approaches leading to a better quality of life, according to findings from a discussion with patients from six countries. They also questioned the “concept of remission” in a multiorgan disease…
Four sarcoidosis patients and researchers who work to better understand the disease and raise awareness about it will be honored at the Foundation for Sarcoidosis Research (FSR)’s Inaugural Sarcoidosis Crystal Awards Gala Celebrating Connections, Collaboration, and Catalyzing Research. The gala, which will take place May 24 from 6…
The Lung Allocation Score (LAS) system, which is used to prioritize patients awaiting lung transplant, may not accurately reflect disease severity risks for people with pulmonary sarcoidosis, a new study reports. Results showed that several factors accounted for in the LAS remain significant predictors of mortality for patients on…
Researchers have uncovered a network of abnormally activated immune cells and fibroblasts — the primary active cell of connective tissue — within granulomas, the clumps of cells that cause sarcoidosis. The key players in granuloma formation include metabolically reprogrammed immune macrophages, immune T-helper (Th) cells producing pro-inflammatory molecules, and…
A clinical trial is testing whether a smartphone app called SPARC, which prompts users to perform meditative breathing exercises and contains disease-relevant education modules, can help ease fatigue and improve life quality for people with sarcoidosis. The study (NCT05230693), sponsored by the Medical University of South Carolina, is…
Findings of defects in the heart’s right ventricle, as assessed with an MRI scan, can predict the occurrence of cardiovascular events in people with confirmed or suspected cardiac sarcoidosis, a review study showed. Particularly, scarring in the right ventricle muscle was a “strong independent predictor” of sudden heart-related death,…
The Multidisciplinary Sarcoidosis Clinic at the University of Alabama at Birmingham Marnix E. Heersink School of Medicine has joined as a founding member of the Global Sarcoidosis Alliance, an initiative led by the Foundation for Sarcoidosis Research (FSR). The alliance has nearly 40 founding members, with the…
The European Commission (EC) has granted orphan drug designation to aTyr Pharma’s lead therapeutic candidate efzofitimod for treating sarcoidosis. Orphan drug status is granted to investigational therapies that show significant potential for treating chronic or life-threatening disease that affect no more than five in 10,000 people in the…
Get regular updates to your inbox.